Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients

RT @MayoPCCM: #DrEvaCarmona, #DrDagnyAnderson, @aeganMD, @AndrewLimper, and colleagues found no differences between autologous adipose-deri…

#DrEvaCarmona, #DrDagnyAnderson, @aeganMD, @AndrewLimper, and colleagues found no differences between autologous adipose-derived #mesenchymal #stemcells from #IPF patients and healthy controls suggesting they may be an acceptable option for #IPF #therapy.

RT @MayoPCCM: #DrEvaCarmona #DrDagnyAnderson @aeganMD @AndrewLimper & et al found no differences between adipose-derived #mesenchymal #stem…

#DrEvaCarmona #DrDagnyAnderson @aeganMD @AndrewLimper & et al found no differences between adipose-derived #mesenchymal #stemcell (aMSC) properties from #IPF patients & healthy controls suggesting that autologous aMSCs may be an acceptable therapy